Topics
Dr. Kai from Safety BU to Deliver an Oral Presentation at the 9th Drug Discovery & Lead Optimization Conference
2025.09.18
Dr. Kiyonori Kai from the Safety Business Unit, will deliver an oral presentation at The 9th Drug discovery & Lead optimization conference, to be held from October 6 to 8, 2025, in Texas, USA.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.
Conference Name: The 9th Drug discovery & Lead optimization conference
Date & Time: October 7, 2025, 10:35-10:55 (CDT)
Title: Pathophysiological significance of vacuolization in renal tubular epithelium in various renal toxicity models of rats
Presenter: Kiyonori Kai Ph.D, Safety Business Unit
Presentation Summary
The kidney is a vital organ responsible for filtration in the glomerulus, reabsorption and secretion in the tubules, and production and secretion of various bioactive substances. Among the cells constituting the kidney, the tubular epithelium is particularly susceptible to toxicity target following short-term exposure. Proximal tubular epithelium exhibits high reabsorption capacity and microvacuoles are physiologically observed. In toxicity studies, vacuolation of tubular epithelium is frequently observed; however, its mechanisms vary. Even when vacuolation is noted histopathologically, verification of the mechanism may reveal it to be a physiological response, and it is sometimes judged to be non-adverse finding. This presentation will comprehensively evaluate the pathophysiological significance of vacuolation of tubular epithelium induced in rats by various toxicity mechanisms. This presentation will comprehensively evaluate the pathophysiological significance of proximal tubular epithelial vacuolation induced in rats by various drugs with different toxic mechanisms. This evaluation will be based on histopathological examinations using light and electron microscopy, urinary biomarkers, creatinine clearance, and in situ hybridization. The presentation will focus on renal toxicity assessment methods critical for determining toxicological significance.
Axcelead DDP’s Soulution
Axcelead DDP has established a robust drug discovery research platform that enables accurate evaluation, including the assessment of toxicological significance across various organ systems including nephrotoxicity. Should you encounter challenges in interpreting pathological changes identified during exploratory safety assessments, conducting mechanism-of-action toxicity studies, preparing regulatory submissions, or planning nonclinical safety testing, we encourage you to consult with us.
Kiyonori Kai, Ph.D, Safety Business Unit
He joined Asahi Kasei in 1992, transferred to Daiichi Pharmaceutical in 2000, and transferred to Daiichi Sankyo. He studied abroad at North Carolina State University in 2008, conducting joint research with NIHES. At Daiichi Sankyo, served as Group Leader for Clinical and Pathological Testing and Chair of the Safety Strategy Planning Committee, leading activities from exploratory to late-stage drug development, life cycle management, and in-licensed product evaluation. Assumed current position in April 2025. Outside the company, he is involved with the International Harmonization of Nomenclature and Diagnostic Criteria (Dog), the Predictive Safety Testing Consortium, and the Life Intelligence Consortium. He serves as a council member and editorial board member for the Japanese Society of Toxicologic Pathology, and as a council member for the Japan Veterinary Medical Association and the Japanese Society of Veterinary Pathology.